All material subject to strictly enforced copyright laws. © 2022 Euromoney Institutional Investor PLC group

Idorsia raises Sfr600m to fund drug commercialisation


Idorsia, the Swiss biotech company, has turned to the convertible bond market to finance looming product launches and the development of its late-stage drug pipeline.

Unlock this article.

The content you are trying to view is exclusive to our subscribers.

To unlock this article:

Take a Free Trial or Login
We use cookies to provide a personalized site experience.
By continuing to use & browse the site you agree to our Privacy Policy.
I agree